论文部分内容阅读
作者从1974年就已证明,从乙型肝炎表面抗原(HBsAg)阴性血浆制备的C_1脂酶抑制剂浓缩物(HBsAg阴性)能引起乙型肝炎(乙肝)的传染。但当制剂加有乙肝免疫球蛋白(HBIg)后,病人无输血后肝炎发生。为了探讨血浆衍生物(因子Ⅷ浓缩物、凝血酶原复合物、C_1脂酶抑制剂浓缩物、纤维蛋白溶酶酶原和抗凝血酶Ⅲ等5种)中添加剂量相对较小些的HBIg,是否也具有消除乙肝潜在性的作用,作者等对12只黑猩猩进行了实验观察。制备前述5种血浆衍生物的原料血浆4950ml来自23份HBsAg及抗HBs均阴性的供者混合血浆,加10
The authors have shown since 1974 that C 1 lipase inhibitor concentrates (HBsAg negative) prepared from hepatitis B surface antigen (HBsAg) negative plasma can cause the transmission of hepatitis B (hepatitis B). However, when the preparation plus hepatitis B immunoglobulin (HBIg), the patient did not produce blood transfusion after hepatitis. In order to investigate the effect of HBIg on plasma derivatives (factor Ⅷ, prothrombin complex, C-1 lipase inhibitor concentrate, plasminogen and antithrombin Ⅲ) , Whether it also has the role of eliminating the potential of hepatitis B, the authors conducted an experimental observation of 12 chimpanzees. The starting plasma of the above 5 plasma derivatives, 4950 ml, was obtained from 23 mixed donor donors negative for both HBsAg and anti-HBs plus 10